中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
16期
56-57
,共2页
非酒精性脂肪肝%C-反应蛋白%2型糖尿病%胰岛素抵抗
非酒精性脂肪肝%C-反應蛋白%2型糖尿病%胰島素牴抗
비주정성지방간%C-반응단백%2형당뇨병%이도소저항
Non -alcoholic fatty liver%C-reactive protein%Type 2 diabetes%Insulin resistance
目的 研究2型糖尿病合并非酒精性脂肪肝患者血清C-反应蛋白与胰岛素抵抗的关系.方法 选择30例2型糖尿病合并非酒精性脂肪肝、32例2型糖尿病患者及25例正常人,检测空腹血糖、血脂、空腹胰岛素、超敏C-反应蛋白、体质量指数(BMI)和腰臀比(WHR).采用稳态模式评估法计算胰岛素抵抗指数(HOMA-IR).结果 脂肪肝组甘油三酯、低密度脂蛋白胆固醇、空腹胰岛素、HOMA-IR、BMI、WHR较非脂肪肝组明显升高.两组血糖比较差异无统计学意义(P＞0.05).结论 2型糖尿病合并非酒精性脂肪肝患者较未并发脂肪肝患者存在明显的胰岛素抵抗、脂质代谢异常及肥胖；改善肝脏脂肪代谢,减轻炎症状态可能有利于减轻胰岛素抵抗.
目的 研究2型糖尿病閤併非酒精性脂肪肝患者血清C-反應蛋白與胰島素牴抗的關繫.方法 選擇30例2型糖尿病閤併非酒精性脂肪肝、32例2型糖尿病患者及25例正常人,檢測空腹血糖、血脂、空腹胰島素、超敏C-反應蛋白、體質量指數(BMI)和腰臀比(WHR).採用穩態模式評估法計算胰島素牴抗指數(HOMA-IR).結果 脂肪肝組甘油三酯、低密度脂蛋白膽固醇、空腹胰島素、HOMA-IR、BMI、WHR較非脂肪肝組明顯升高.兩組血糖比較差異無統計學意義(P＞0.05).結論 2型糖尿病閤併非酒精性脂肪肝患者較未併髮脂肪肝患者存在明顯的胰島素牴抗、脂質代謝異常及肥胖；改善肝髒脂肪代謝,減輕炎癥狀態可能有利于減輕胰島素牴抗.
목적 연구2형당뇨병합병비주정성지방간환자혈청C-반응단백여이도소저항적관계.방법 선택30례2형당뇨병합병비주정성지방간、32례2형당뇨병환자급25례정상인,검측공복혈당、혈지、공복이도소、초민C-반응단백、체질량지수(BMI)화요둔비(WHR).채용은태모식평고법계산이도소저항지수(HOMA-IR).결과 지방간조감유삼지、저밀도지단백담고순、공복이도소、HOMA-IR、BMI、WHR교비지방간조명현승고.량조혈당비교차이무통계학의의(P＞0.05).결론 2형당뇨병합병비주정성지방간환자교미병발지방간환자존재명현적이도소저항、지질대사이상급비반；개선간장지방대사,감경염증상태가능유리우감경이도소저항.
Objective To investigate the relationship between serum C-reactive and insulin resistance in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver.Methods Thirty cases of type 2 diabetic patients complicated with NAFLD,32 cases of type 2 diabetic patients and 25 cases of healthy volunteers were choosed.Fasting insulin levels (FINS),glucose and high sensitivity C reactive protein(CRP) were measured.At the same time,body weight index (BMI),the waist hip ratio (WHR) were also calculated.The index of IR was calculated according to the HOMA method.Results Compared with the non-fatty liver group,the average levels of TG,LDL-C,FINS,HOMA-IR,BMI and WHR were significantly higher in fatty liver group (P ＜ 0.05 ).There was no significant difference in blood glucose level between the two groups (P ＞ 0.05).Conclusions T2DM patients complicated with NAFLD have more serious IR,dyslipidemia and obesity; Amelioration of lip metabolism in liver and mitigation of inflammation may help to reduce the extent of IR.
